Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

5.1%

22 terminated/withdrawn out of 430 trials

Success Rate

68.1%

-18.5% vs industry average

Late-Stage Pipeline

8%

33 trials in Phase 3/4

Results Transparency

0%

0 of 47 completed trials have results

Key Signals

179 recruiting12 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 2
162(42.1%)
Phase 1
96(24.9%)
N/A
68(17.7%)
Early Phase 1
26(6.8%)
Phase 4
20(5.2%)
Phase 3
13(3.4%)
385Total
Phase 2(162)
Phase 1(96)
N/A(68)
Early Phase 1(26)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (430)

Showing 20 of 430 trials
NCT07850362Not ApplicableCompleted

Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA

Role: lead

NCT07850375Not ApplicableNot Yet Recruiting

Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT07115654Phase 2Recruiting

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Role: lead

NCT07840976Phase 2Not Yet Recruiting

Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL

Role: lead

NCT07836127Not ApplicableNot Yet Recruiting

Human Albumin Combined With Plasma Exchange for Frailty Intervention

Role: lead

NCT05376345Phase 1Completed

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT07714512Phase 1Recruiting

Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia

Role: lead

NCT07692529Phase 1Not Yet Recruiting

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

Role: lead

NCT07689604Early Phase 1Not Yet Recruiting

META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia

Role: lead

NCT07830485Phase 2Not Yet Recruiting

CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Role: lead

NCT07831395Phase 2Not Yet Recruiting

Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL

Role: lead

NCT07828522Phase 2Not Yet Recruiting

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Role: lead

NCT07809594Phase 1Active Not Recruiting

CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma

Role: lead

NCT06948981Phase 1Recruiting

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Role: collaborator

NCT07578675Recruiting

Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

Role: lead

NCT07828535Phase 1Not Yet Recruiting

Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

Role: lead

NCT06931912Not ApplicableActive Not Recruiting

Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia

Role: lead

NCT07652905Phase 2Recruiting

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

Role: lead

NCT07585760Phase 2Recruiting

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

Role: lead

NCT07816341Phase 1Not Yet Recruiting

Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia

Role: lead